Pharmasia Ltd
Fundamental Score
Pharmasia Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of PHRMASI across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (371.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (179.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (21.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (73.51%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
11 factors identified
Below-Average Return on Equity (-16.70%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-16.47%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-5.35%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Premium Valuation Risk (P/E: 57.57x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Limited Growth History (4.10% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Limited Institutional Interest (FII+DII: 0.05%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Pharmasia Ltd
About PHRMASI
Business Overview
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. It offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. The company provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
Company Details
Key Leadership
Latest News
PHRMASI Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Pharmasia Ltd (PHRMASI)?
As of 09 Feb 2026, 12:22 pm IST, Pharmasia Ltd (PHRMASI) is currently trading at ₹108.81. The stock has a market capitalization of ₹44.91 (Cr).
Is PHRMASI share price Overvalued or Undervalued?
PHRMASI is currently trading at a P/E ratio of 57.57x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Pharmasia Ltd share price?
Key factors influencing PHRMASI's price include its quarterly earnings growth (Sales Growth: 179.09%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Pharmasia Ltd a good stock for long-term investment?
Pharmasia Ltd shows a 5-year Profit Growth of N/A% and an ROE of -16.70%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Pharmasia Ltd compare with its industry peers?
Pharmasia Ltd competes with major peers in the Pharmaceuticals. Investors should compare PHRMASI's P/E of 57.57x and ROE of -16.70% against the industry averages to determine its competitive standing.
What is the P/E ratio of PHRMASI and what does it mean?
PHRMASI has a P/E ratio of 57.57x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹58 for every ₹1 of annual earnings.
How is PHRMASI performing according to Bull Run's analysis?
PHRMASI has a Bull Run fundamental score of 34.7/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does PHRMASI belong to?
PHRMASI operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Pharmasia Ltd.
What is Return on Equity (ROE) and why is it important for PHRMASI?
PHRMASI has an ROE of -16.70%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Pharmasia Ltd generates profits from shareholders' equity.
How is PHRMASI's debt-to-equity ratio and what does it indicate?
PHRMASI has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is PHRMASI's dividend yield and is it a good dividend stock?
PHRMASI offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has PHRMASI grown over the past 5 years?
PHRMASI has achieved 5-year growth rates of: Sales Growth 4.10%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in PHRMASI and why does it matter?
Promoters hold 73.51% of PHRMASI shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is PHRMASI's market capitalization category?
PHRMASI has a market capitalization of ₹45 crores, placing it in the Small-cap category.
How volatile is PHRMASI stock?
PHRMASI has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for PHRMASI?
PHRMASI has a 52-week high of ₹N/A and low of ₹N/A.
What is PHRMASI's operating profit margin trend?
PHRMASI has a 5-year average Operating Profit Margin (OPM) of -5.35%, indicating the company's operational efficiency.
How is PHRMASI's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 179.09% and YoY Profit Growth of 371.88%.
What is the institutional holding pattern in PHRMASI?
PHRMASI has FII holding of 0.00% and DII holding of 0.05%. Significant institutional holding often suggests professional confidence in the stock.